CURIS ANNOUNCES THE RECEIPT OF SECOND EXTENSION OF FUNDING FROM GENENTECH

Curis, Inc., a therapeutic drug development company, today announced that, for the second time this year, Genentech has elected to extend funding of the cancer therapeutic development collaboration that is ongoing between the two companies. An additional $1.25 million will be provided to support Curis personnel dedicated to developing Curis' Hedgehog antagonist technologies for the treatment of solid tumor cancers for the period of December 2005 through June 2006. Genentech had previously supported Curis personnel and additional third party resources managed by Curis scientists. The progress made by the two companies has reduced the need for these third party resources.

Business Wire (http://home.businesswire.com/portal/site/google/index.jsp?ndmViewId=news_view&newsId=20051013005613&newsLang=en)